Clinical Trials Browser

Phase 1/2 × Has results × Salivary Gland Neoplasms × Clear all

NCT02538510 2024-11-26

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Phase 1/2 Completed

50 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms

NCT03749460 2023-12-29

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Phase 1/2 Completed

20 enrolled 12 charts

Salivary Gland Neoplasms

NCT01816984 2021-10-05

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Phase 1/2 Completed

12 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT01806675 2019-10-03

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Phase 1/2 Completed

25 enrolled 14 charts

BreastCNSGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gliosarcoma, Breast Neoplasms, Male